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The control of orzchoceiriasis renzains a priority in 
sub-Saharan Africa. Jeaiz-Philippe Clzippaux, Michel 
Boussiiiesq, Jncques Gardon, Natlzalie Gardoiz- Weizdel and 
Jean-Clzristoplze Erizould here outline studies coizceriziizg 
possible severe adverse renctioizs to iverinecfin used to con- 
trol oizclzocerciasis in areas wlzere loiasis is also erzdeiizic, 
and discuss precautioizs tlzaf inay be advisable during the 
iinpleiizeiztntioiz of suclz prograinmes. 
Ivermectin treatment has drastically changed the 
approach of onchocerciasis control programmes in 
the past decade. First trials conducted in African 
savannah, where tlie severity of onchocerciasis is well 
established, showed the good tolerance of ivermectin 
and tlie feasibility of large-scale treatments against 
onchocerciasis in these areas’. The development of 
this strategy in Central Africa is in progress. The 
extension of these programmes in forest areas of 
Africa where onchocerciasis Co-exists with loiasis 
brought into question tlie tolerance of ivermectin in 
patients infected with Loa loa. These studies are par- 
ticularly important because severe adverse reactions 
following treatment with diethylcarbamazine (DEC) 
are observed in patients infected with Loa lon. First tri- 
als conducted in areas endemic for loiasis showed 
that ivermectin is well tolerated>, even in patients 
with high level of Loa loa microfilariae (Mf) in their 
bl00d3. Following these results, large-scale treatment 
against onchocerciasis was implemented in areas 
endemic for loiasis. At the same time, trials for large- 
scale treatment against loiasis were done4. As these 
programmes progressed, several suspect cases were 
observed that led us to resume trials of ivermectin in 
loiasis patients with very high parasitaemia. 
Assessing the situation 
In South Cameroon, several patients presented se- 
vere problems days to weeks following ivermectin 
treatment. For eight of these patients, we failed to 
find any cause to explain their problems; these cases 
are documented in Table 1. One of these patients died 
23 days after.tlie dosing. It was impossible to attribute 
this death to ivermectin5. An accurate frequency for 
these severe problems, however, is difficult to obtain; 
the total number of people receiving ivermectin treat- 
ment is difficult to evaluate in areas endemic for 
loiasis because, in tliese areas, many teams are in- 
vo lved in ivermectin distribution. We assuine that the i I 
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number of subjects treated with iverinectin in South 
Cameroon exceeds 100 000. In addition, the procedure 
for surveillance of programmes varies from one pro- 
gramme to another, and so it is probable that not all 
cases of severe side effects have been reported. 
The Loa loa microfilaraemia before treatment was 
known in four of the eight patients who presented 
severe neurological complaints (Table 1). Para- 
sitaemia of these patients was particularly high. This 
led us to study the tolerance for ivermectin in patients 
with very high Loa loa microfilaraemia. Some 112 vol- 
unteers, whose parasitaemia before treatment was 
higher than 3000 Mf ml-1, received ivermectin in 
Hôpital Central, Yaoundé6. The purpose of this study 
was twofold: (1) to determine the threshold of micro- 
filaraemia above which adverse reaction risks could 
appear; and (2) to establish which indicators permit 
identification of people at risk! Clinical and biological 
examinations of patients were made daily. We ob- 
served clinical and biological inflammatory signs 
(fever, headache, myalgia, arthralgia, increase of 
C-reactive protein), renal impairment (proteinuria, 
haematuria) and neurological disorders (asthenia, 
reduction of the activity, stupor). The presence of Loa 
loa Mf was observed in cerebro-spinal fluid (CSF) of 
several patients after treatment. One of them pre- 
sented a stage 2 coma, ie. he reacted to aching stimu- 
lation but was unable to reply to questions. He recov- 
ered three weeks later after a simple symptomatic 
treatment (analgesic, anti-inflammatory, anti-allergic 
and diuretic). The severity of the symptoms was 
closely related to the level of the parasitaemia before 
treatment. The fever seemed to be the first objective 
sign revealing the presence of severe adverse reac- 
tions. It appeared the day following treatment, and. 
lasted two or three days. The passage of the Mf in tlie 
CSF was progressive from tlie first day, increasing 
until Days 4-6, and then decreasing slowly. In ten 
patients who underwent lumbar puncture (LP) before 
and after treatment, we confirmed that tlie passage of 
tlie Mf in CSF was linked to tlie treatment, whereas 
the density of Mf in CSF was proportional to the 
initial parasitaemia. The incidence of adverse reaction 
in patients with parasitaemia higher than 15 O00 Mf 
ml-1 before treatment was significantly higher than 
for other patients. When parasitaemia before treat- 
ment was higher than 30000 Mf nil-1, severity of 
adverse reactions was obvious in most of the patients. 
The only patient showing a Karnofsky’s index (a clin- 
ical score assessing the mobility and autonomy of 
patients presenting neurological disorders) below 
70% presented more than 150000 Mf mI-1 before 
treatment. This value of the Karnofsky’s index indi- 
cates a loss of autonomy, necessitating liospitaliz- 
ation; for several days tlie patient needed assistance 
to feed and drink. 
Table I. Severe adverse reactions following treatment with ivermectin 
Vi I lage 
Age Isex 
Parasitaemia 
(Mf ml-1) 
Associated 
parasites 
lvermectinc 
dose (pg kg-') 
First symptoms 
(Day I) 
Time to report (h) 
Fever (>38"C) 
Main symptom 
reported 
Main symptom 
observed 
% disability 
(Day 31Day 8) 
Mf in CSFd 
Evolution 
Case I Case 2 
Nrui Ntui 
201M 401F 
I39 O00 I02 O00 
o. volvulus o. volvulus 
(250 per (140 per 
skin-snip) skin-snip) 
M. perstans M. perstons 
I800 Mf ml-l) (650 Mf ml-1) 
200 200 
Asthenia? Headache 
asthenia? 
24 24 
Yes Yes 
Stupor Stupor 
Lethargy Lethargy 
(Dar 1) (Day 2) 
50 50 
Case 3 Case 4 Case 5 
Poumaa Elig Mfomo Nkolassi 
37/M 69lM 441M 
? 'Many' at 'Few' at 
Day I7 after Day 7 after 
treatment treatment 
o. volvulus ? ? 
(?) 
I50 150 I50 
? ? Asthenia 
anorexia 
72 ? 24 
Yes No a t  Day 17 Yes 
Stupor Stupor ? 
(Day 4) (Day 6) 
(Day 17) 
Stupor Stupor 
>80 ? ? 
Case 6 
Mbakamo 
421M 
? 
? 
I50 
Asthenia 
24 
Yes 
? 
? 
'Few' at Day 4 
Case 7 
Ngatb 
27lM 
I99 O00 
None 
200 
Headache 
asthenia 
48 
Yes 
Coma 
(Day 3) 
70 
Case 8 
Ngatb 
591F 
217000 
o. volvulus 
(7 per 
skin-snip) 
200 
Headache 
asthenia 
48 
No 
Stupor 
(Dar 4) 
50 
? ? >IO0 Mf ml-1 ? ? 
(Day 4) 
Recovery Recovery Death Recovery Left hospital Left hospital 
(Day21) (Day 15) (Day23) (Day 25) (Day20) (Day IO) (Day21) (Day 15) 
a Ref. 5. 
Ref. 7. 
Day O, day treatment (ivermectin dose) given. 
CSF, cerebrospinal fluid. 
Collating available data 
The frequency of severe adverse reactions occur- 
ring during large-scale treatment with ivermectin in 
areas endemic for loiasis can be estimated by combin- 
ing observations collected during the clinical study6 
(reported above) and epidemiological data on the pre- 
valence of people with high Loa loa parasitaemia. Sur- 
veys were performed in 46 selected villages according 
to a cline between savannah and forest zones in 
Cameroon (M. Boussinesq, unpublished). Blood sam- 
ples (thick smears of 30 ml) were taken between 
10.00 ain and 3.00 pin. Prevalence of young people 
(under 15 years) with parasitaemia higher than 30 O00 
Mf ml71 was negligible. The prevalence of adults pre- 
senting more tlian 30000 Mf m l - 1  ranged between 
0.5% at the border of savannah to 4% in dense forest 
zone. The population at risk, therefore, essentially 
comprised adults, and represented about 50% of the 
general population. 
The evaluation of the prevalence of severe neuro- 
logical adverse reactions obtained from data collected 
during large-scale treatments corroborates the find- 
ings of the hospital trial. Population at risk can be 
estimated at about 200 subjects out of 10000 people 
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Recovery Recovery 
living in areas endemic for loiasis, and severe adverse 
reactions could occur in 5-10 of these people. 
Recommendations 
Therefore, severe adverse reaction risks should be 
considered during large-scale treatments with iver- 
inectin in areas endemic for loiasis, and our obser- 
vations indicate that precautions are advisable during 
the implementation of such programmes. On the one 
hand, it is necessary to define more accurately the cri- 
teria of choice for people who need ivermectin treat- 
ment. On the other hand, we think that it is desirable 
to modify implementation of large-scale treatment with 
ivermectin. We recommend the following measures: 
(1) Information of treated population will have to 
specify risks of adverse reactions, clinical predictive 
signs of suc11 reactions (fever, headache, myalgia, 
arthralgia) and to incite patients or their carers to 
report such symptoms immediately to surveillance 
teains in order to receive treatment (analgesic, anti- 
inflammatory, anti-allergic and diuretic) and advice 
concerning their food and beverage regimens. 
(2) Post-treatment surveillance will liave to be im- 
proved and, besides the recoinmended surveillance in 
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the 36 h following the treatment, a further visit in the 
treated community will be required on Day 3 4  to 
check patients presenting severe adverse reactions 
(fever, reduction of activity, stupor, coma) and to trans- 
port them to a place where dispensary or hospital 
therapeutic management will be ensured. 
(3) A system of pharmacovigilance should be orga- 
nized in areas endemic for loiasis to document these 
adverse reactions. 
Because this is an important problem, it seemed use- 
ful to be aware of possible severe adverse reactions 
after treatment witl; ivermectin in Central Africa, and 
to take all possible precautionary measures during 
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I Coming soon to  a screen near you! 
From our sister journal, Trends in Genetics: an essential new resource for molecular biologists and geneticists - 
Technical Tips Online. 
This new'electronic publication forum, available on the World Wide Web, builds on the success and popularity of 
the Technical Tips section in Trends in Genetics. It is designed as both a journal of rigorously peer-reviewed articles 
and a database that will develop into a unique resource of molecular biology techniques information. 
Technical Tips Online will include facilities for comments and questions to authors, and these will be posted along 
with the relevant article. 
For the remainder of 1996, Trends in Genetics will be including a bumper Technical Tips section, so that these Tips 
can be published both in Trends in Genetics and in Technical Tips Online. From 1997, as the number of articles 
increases, there will be a listing in Trends in Genetics of the titles and authors of Tips published electronically. 
If you would like information about how to submit a Tip for publication in Technical Tips Online please send an 
e-mail to TTO@eIsevier.co.uk 
Elsevier Trends Journals thanks all Technical Tips authors for their comments and enthusiasm for the launch of 
Technical Tips Online. 
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